InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Fox News First and San Antonio Living
17 February 2012 - 11:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a
developer of groundbreaking technologies for the treatment of
spinal cord injuries (SCI), today announced that CEO Frank Reynolds
is scheduled to appear on San Antonio’s Fox News First on KABB-TV
on Wednesday, February 22nd during their 7:00 AM (CST) newscast.
Reynolds is also scheduled to appear the same day on San Antonio
Living on WOAI-TV that airs from 10:00 to 11:00 AM (CST).
InVivo Therapeutics has pioneered a new treatment platform that
uses a biocompatible polymer-based scaffold to provide structural
support to a damaged spinal cord in order to spare tissue from
scarring while improving recovery and prognosis after a traumatic
spinal cord injury. Reynolds will discuss the scaffold and how it
is expected to work in humans, as well as results from InVivo’s
largest non-human primate study.
“We expect that our technology will change the standard care for
spinal cord injury treatment. We’re currently under review at FDA
and we look forward to receiving approval to begin human studies,”
said Reynolds. “Our therapeutic approach confirms a clear paradigm
shift in the treatment of spinal cord injuries.”
Fox News First is the morning show that airs weekdays from 5:00
– 9:00 am CST on KABB-TV, the local FOX affiliate in San Antonio,
Texas. San Antonio Living is a daytime talk show that airs on
WOAI-TV, the local NBC affiliate in San Antonio.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a
platform technology to develop treatments to improve function in
individuals paralyzed from traumatic spinal cord injuries. The
company was founded in 2005 based on proprietary technology
co-invented by Robert S. Langer, ScD. Professor at Massachusetts
Institute of Technology, and Joseph P. Vacanti, M.D., who is
affiliated with Massachusetts General Hospital. In 2011, the
company earned the prestigious 2011 David F. Apple Award from the
American Spinal Injury Association for its outstanding contribution
to spinal cord injury medicine. The publicly traded company is
headquartered in Cambridge, Mass. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company’s
ability to sell additional shares of common stock and warrants to
purchase common stock at additional closings, the Company’s ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the
Company’s business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
our filings with the SEC, including our Form 10-K and Form 10-Qs
and our current reports on Form 8-K. We do not undertake to update
these forward-looking statements made by us.